Phenelzine, a notable example of a potent non-selective and irreversible MAO-A inhibitor, is currently under investigation in clinical trials for the treatment of prostate cancer [50] [Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer, NCT02217709]. The gene discussed is MAOA; the disease is prostate carcinoma.